Wergeland S - Search Results

1

Increasing serum levels of vitamin A, D and E are associated with alterations of different inflammation markers in patients with multiple sclerosis.

Røsjø E, Myhr KM, Løken-Amsrud KI, Bakke SJ, Beiske AG, Bjerve KS, Hovdal H, Lilleås F, Midgard R, Pedersen T, Benth JS, Torkildsen Ø, Wergeland S, Michelsen AE, Aukrust P, Ueland T, Holmøy T. Røsjø E, et al. Among authors: wergeland s. J Neuroimmunol. 2014 Jun 15;271(1-2):60-5. doi: 10.1016/j.jneuroim.2014.03.014. Epub 2014 Mar 24. J Neuroimmunol. 2014. PMID: 24713402 Clinical Trial.

2

IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis.

Wergeland S, Beiske A, Nyland H, Hovdal H, Jensen D, Larsen JP, Marøy TH, Smievoll AI, Vedeler CA, Myhr KM. Wergeland S, et al. Eur J Neurol. 2005 Mar;12(3):171-5. doi: 10.1111/j.1468-1331.2004.01102.x. Eur J Neurol. 2005. PMID: 15693804 Clinical Trial.

3

Dietary vitamin D3 supplements reduce demyelination in the cuprizone model.

Wergeland S, Torkildsen Ø, Myhr KM, Aksnes L, Mørk SJ, Bø L. Wergeland S, et al. PLoS One. 2011;6(10):e26262. doi: 10.1371/journal.pone.0026262. Epub 2011 Oct 20. PLoS One. 2011. PMID: 22028844 Free PMC article.

4

ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial.

Torkildsen O, Wergeland S, Bakke S, Beiske AG, Bjerve KS, Hovdal H, Midgard R, Lilleås F, Pedersen T, Bjørnarå B, Dalene F, Kleveland G, Schepel J, Olsen IC, Myhr KM. Torkildsen O, et al. Among authors: wergeland s. Arch Neurol. 2012 Aug;69(8):1044-51. doi: 10.1001/archneurol.2012.283. Arch Neurol. 2012. PMID: 22507886 Clinical Trial.

5

Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment.

Løken-Amsrud KI, Holmøy T, Bakke SJ, Beiske AG, Bjerve KS, Bjørnarå BT, Hovdal H, Lilleås F, Midgard R, Pedersen T, Benth JS, Sandvik L, Torkildsen O, Wergeland S, Myhr KM. Løken-Amsrud KI, et al. Among authors: wergeland s. Neurology. 2012 Jul 17;79(3):267-73. doi: 10.1212/WNL.0b013e31825fdf01. Epub 2012 Jun 13. Neurology. 2012. PMID: 22700809

6

The cuprizone model: regional heterogeneity of pathology.

Wergeland S, Torkildsen Ø, Myhr KM, Mørk SJ, Bø L. Wergeland S, et al. APMIS. 2012 Aug;120(8):648-57. doi: 10.1111/j.1600-0463.2012.02882.x. Epub 2012 Feb 24. APMIS. 2012. PMID: 22779688

7

Retinol levels are associated with magnetic resonance imaging outcomes in multiple sclerosis.

Løken-Amsrud KI, Myhr KM, Bakke SJ, Beiske AG, Bjerve KS, Bjørnarå BT, Hovdal H, Lilleås F, Midgard R, Pedersen T, Benth JS, Torkildsen Ø, Wergeland S, Holmøy T. Løken-Amsrud KI, et al. Among authors: wergeland s. Mult Scler. 2013 Apr;19(4):451-7. doi: 10.1177/1352458512457843. Epub 2012 Aug 20. Mult Scler. 2013. PMID: 22907941

8

Fat-soluble vitamins as disease modulators in multiple sclerosis.

Torkildsen Ø, Løken-Amsrud KI, Wergeland S, Myhr KM, Holmøy T. Torkildsen Ø, et al. Among authors: wergeland s. Acta Neurol Scand Suppl. 2013;(196):16-23. doi: 10.1111/ane.12045. Acta Neurol Scand Suppl. 2013. PMID: 23190287

9

A need for national registries and international collaborative research in multiple sclerosis.

Myhr KM, Grytten N, Torkildsen Ø, Wergeland S, Bø L, Pugliatti M, Aarseth JH. Myhr KM, et al. Among authors: wergeland s. Acta Neurol Scand Suppl. 2012;(195):1-3. doi: 10.1111/ane.12039. Acta Neurol Scand Suppl. 2012. PMID: 23278648

10

Polyunsaturated fatty acids in multiple sclerosis therapy.

Wergeland S, Torkildsen Ø, Bø L, Myhr KM. Wergeland S, et al. Acta Neurol Scand Suppl. 2012;(195):70-5. doi: 10.1111/ane.12034. Acta Neurol Scand Suppl. 2012. PMID: 23278660 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

58 results

Search Page